Terminated PHASE4 INTERVENTIONAL 3-arm NCT03196349

Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism (COVET)

Sponsor: Duke University

Interventions Apixaban 2.5 MG Rivaroxaban 10 MG Warfarin

Updated 7 times since 2017 Last updated: Dec 12, 2019 Started: Aug 1, 2018 Primary completion: May 1, 2019 Completion: May 1, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Lack of enrollment

Other terminated trials from Duke University

See all terminations from Duke University

Other Venous Thromboembolism trials with similar outcome

Browse all Venous Thromboembolism trials

Listed as NCT03196349, this PHASE4 trial focuses on Venous Thromboembolism and remains terminated or withdrawn. Sponsored by Duke University, it has been updated 7 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE4
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE4
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE4
Jan 2020 — Jan 2021 [monthly]

Terminated PHASE4
Sep 2019 — Jan 2020 [monthly]

Terminated PHASE4

Status: Recruiting → Terminated

▶ Show 2 earlier versions

Dec 2018 — Sep 2019 [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting · Phase: PHASE3 → PHASE4
Jul 2017 — Dec 2018 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Duke University
Patient-Centered Outcomes Research Institute

Data source: Duke University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Orange, United States